CURRICULUM VITAE
`
`Alexander D. D’Addio, Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`February 2017- Present
`
` October 2001 – February 2017
`
`EDUCATION
`Seton Hall University
`South Orange, New Jersey
`Ph.D. Analytical Chemistry, 1983
`
`Kean University
`Union, New Jersey
`B.A., cum laude, Chemistry, 1975
`
`WORK EXPERIENCE
`
`
`
`DADDIO Pharma Consulting L.L.C.
`
`President
`
`Independent consultant providing support and services for the development, commercial launch,
`and marketing of pharmaceutical products.
`
`Meda Pharmaceuticals Inc., Somerset, NJ
`
`Vice President, Scientific Affairs and Medical Communications October 2015 – Present
`Reports to Executive Vice President, Scientific Affairs, Meda Global Executive Team,
`Meda AB
`
`Responsibilities include the design and execution of studies to demonstrate product attributes in
`support of Medical Affairs and Marketing and presentation of results. Oversight of Medical
`Science Liaisons operations, planning and execution of Advisory boards, Congresses and
`Investigator Initiated Study interactions. Oversight of Clinical Research and Operations.
`Support the development of product line extensions including NDA and non-NDA prescription
`products. Support the development and validation of commercial processes and analytical
`methods required to bring products to market. Provide technical and analytical chemistry
`support to Quality Assurance, Regulatory Affairs and Manufacturing. Identify, recommend, and
`manage activities at contract facilities for analytical method development and validation. Support
`the evaluation of new products. Assess potential and risks associated with acquisition of new
`products. Responsible for the development and review of patents and maintenance of intellectual
`property.
`
`Vice President, Scientific and Analytical Affairs
`
`Vice President, Technical and Scientific Affairs
`
`
`
`
`Page 1 of 4
`
`
`
` August 2013-October 2015
`
` October 2012 – August 2013
`
`CIP2004
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`1
`
`
`
`Alexander D. D’Addio, Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`February 2017- Present
`
` October 2001 – February 2017
`
`EDUCATION
`Seton Hall University
`South Orange, New Jersey
`Ph.D. Analytical Chemistry, 1983
`
`Kean University
`Union, New Jersey
`B.A., cum laude, Chemistry, 1975
`
`WORK EXPERIENCE
`
`
`
`DADDIO Pharma Consulting L.L.C.
`
`President
`
`Independent consultant providing support and services for the development, commercial launch,
`and marketing of pharmaceutical products.
`
`Meda Pharmaceuticals Inc., Somerset, NJ
`
`Vice President, Scientific Affairs and Medical Communications October 2015 – Present
`Reports to Executive Vice President, Scientific Affairs, Meda Global Executive Team,
`Meda AB
`
`Responsibilities include the design and execution of studies to demonstrate product attributes in
`support of Medical Affairs and Marketing and presentation of results. Oversight of Medical
`Science Liaisons operations, planning and execution of Advisory boards, Congresses and
`Investigator Initiated Study interactions. Oversight of Clinical Research and Operations.
`Support the development of product line extensions including NDA and non-NDA prescription
`products. Support the development and validation of commercial processes and analytical
`methods required to bring products to market. Provide technical and analytical chemistry
`support to Quality Assurance, Regulatory Affairs and Manufacturing. Identify, recommend, and
`manage activities at contract facilities for analytical method development and validation. Support
`the evaluation of new products. Assess potential and risks associated with acquisition of new
`products. Responsible for the development and review of patents and maintenance of intellectual
`property.
`
`Vice President, Scientific and Analytical Affairs
`
`Vice President, Technical and Scientific Affairs
`
`
`
`
`Page 1 of 4
`
`
`
` August 2013-October 2015
`
` October 2012 – August 2013
`
`CIP2004
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`1
`
`
`
`
`Chief Scientific Officer
`
`Interim Chief Scientific Officer and Senior Director, Technical and Analytical Services
`
`
`
`
`
`
`
`
`
` January 2011 – July 2011
`
`
`
`
`
`
`
`
`
`
`
` July 2011 – October 2012
`
`
`
` December 2001 – December 2010
`
`Vice President, Product and Process Development
`
`Wallace Laboratories, Carter-Wallace, Inc., Cranbury, NJ
`Director, Wallace Technical Services
`
`
`
`
`Responsible for process development and validation, analytical method evaluation and transfer,
`qualification of vendors, and corporate support of commercial manufacturing facilities in
`Cranbury, NJ and Decatur, IL.
`
`Department Head, Wallace Technical Services
`
`Department Head, Research Services
`
`Responsible for analytical support of pharmaceutical development and research stability
`programs, release of clinical supplies, method development and maintenance of reference
`standard program.
`
`Manager, Research Services
`
`Group Leader, Analytical Research
`
`Responsible for supply and certification of reference standards for active pharmaceutical
`ingredients, process impurities and drug degradation products.
`
`Medical Research Div., American Cyanamid Company, Bound Brook, NJ
`Research Scientist, Analytical Research and Development
`
`Responsible for analytical development to support new drug substance process development.
`Implemented Vestec Thermospray/Particle Beam LC/MS and system manager of the HP LAS
`1000 chromatographic data system. Served as Chairperson of the 1987 International Cyanamid
`Technical Research Services Analytical Conference.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 1990 - 2001
` 2000 - 2001
`
` 1996 – 2000
`
` 1994 – 1996
`
` 1993 – 1994
`
` 1990 – 1993
`
` 1984 – 1990
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 2 of 4
`
`2
`
`
`
`MEMBERSHIPS
`American Chemical Society
`American Association of Pharmaceutical Scientists
`
`
`
`PATENTS
`U.S. Patent 6,417,206, “Antitussive/antihistaminics/decongestant compositions” July 9, 2002
`
`U.S. Patent 6,462,094, “Decongestant/expectorant compositions” October 8, 2002
`
`U.S. Patent 6,566,396, “Antitussive/antihistaminics compositions” May 20, 2003
`
`U.S. Patent 8,071,073, “Compositions comprising azelastine and methods of use thereof”
`December 6, 2011
`
`U.S. Patent 8,518,919, “Compositions comprising azelastine and methods of use thereof” August
`27, 2013
`
`U.S. Patent 8,758,816, “Compositions comprising azelastine and methods of use thereof” June
`24, 2014
`
`PUBLICATIONS/PRESENTATIONS
`D’Addio AD, Augustine RL, Ewing GW. An Inelastic Electron Tunneling Spectral (IETS) Study
`of Rhodium Carbonyls Rh6(CO)16 and Rh4(CO)12 Adsorbed on Alumina. Journal of Molecular
`Catalysis. 1988;43:315-325.
`
`D’Addio AD, Luther GW, Meyers L. Voltammetric Methods of Sulfate Ion Analysis in Natural
`Waters. Marine Chemistry. 1978; 6:117-124.
`
`“Inelastic Electron Tunneling Spectroscopy (IETS) and the Study of Supported Metal Catalysts”,
`A.D. D’Addio, and R.L. Augustine, presented at the New York-New England Catalysis Societies
`Spring Symposium, Yale University, March 1982.
`
`“An Automated Content Uniformity Application: From Zymate Tablet Processing Workstation
`to Benchmate”, D.E. Martynuk, A.G. Sheth, D.J. Zuccarello, A.D. D’Addio, H.J. Mortko, K.
`Halloran, presented at ISLAR ’93, Boston, MA.
`
`“Deposition Characteristics of Dymista Nasal Spray (azelastine HCl 137 μg/fluticasone
`propionate 50 μg) in an Anatomical Model of the Human Nasal Cavity”, Alexander D. D’Addio,
`PhD; Nancy M. Ruiz, MD; Larry Gever, PharmD; Michael J. Mayer, PhD; Eli O. Meltzer, MD,
`presented at ACAAI 2014, Atlanta, GA, November 2014
`
`
`
`
`Page 3 of 4
`
`3
`
`
`
`
`“Quantification of the Distribution of MP29-02 (Dymista-Azelastine HCl/Fluticasone Propionate
`Nasal Spray) in an Anatomical Model of the Human Nasal Cavity”, Alexander D. D’Addio,
`PhD; Nancy M. Ruiz, MD; Michael J. Mayer, PhD; William Berger, MD; Eli O. Meltzer, MD,
`presented at AAAAI 2015, Houston, TX, February 2015
`
`“In Vitro Characterization of Flunisolide HFA (Aerospan®) Particle Size and Particle
`Distribution”, Alexander D’Addio, PhD; Eli Meltzer, MD, presented at AAP 2015, Washington
`D.C., October 2015
`
`“In vitro Determination of the Robustness of the Emitted Dose of Flunisolide HFA pMDI”,
`Alexander D’Addio, PhD, David Skoner, MD, Aspen Allergy Conference, July 2016
`
`
`
`
`
`
`
`
`Page 4 of 4
`
`4
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
